Traditional VGSC blockers are known to be inefficient in SCN1A related epilepsies and can even sometimes aggravate seizures in Dravet syndrome, likely due to their limited NaV subtype specificity. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.